TRIB

Business Context and Reporting Period

Company: Trinity Biotech plc
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Business Overview: Trinity Biotech develops, manufactures, and markets medical diagnostic products for clinical laboratory and point-of-care segments globally. Key product areas include infectious diseases, autoimmune disorders, diabetes monitoring, and emergency medicine (cardiac assays). The company operates manufacturing facilities in Ireland and the United States and distributes products in approximately 100 countries.

Key Financial Metrics (Year Ended Dec 31, 2015)

Note: Net financing income in 2015 includes a significant non-cash gain of approximately $13.0 million from the revaluation of embedded derivatives in exchangeable senior notes issued during the year.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by 4.5% to $100.2 million. This was primarily driven by the strengthening of the US Dollar against foreign currencies (Euro, Brazilian Real, Sterling), which reduced reported revenue from international operations. Specific product declines included lower Lyme disease sales (weather-related) and a temporary dip in HIV sales in Q2 2015.
• Operating Profit Decrease: Operating profit fell 25.5% to $13.4 million. This was due to lower gross profit, increased R&D expenses ($5.1 million vs. $4.3 million), and the absence of a $2.0 million non-recurring gain in 2014 related to the release of a contingent consideration accrual.
• Net Profit Increase: Despite lower operating profit, Net Profit increased 26.6% to $21.8 million. This increase is largely attributable to the non-cash financial income of $13.0 million from the revaluation of embedded derivatives on the new exchangeable notes. Excluding this non-cash item, underlying profit after tax would have been approximately $9.3 million.
• Liquidity Surge: Cash and cash equivalents increased dramatically from $9.1 million to $102.0 million, resulting from the issuance of $115 million in exchangeable senior notes in April 2015.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Dividend Suspension & Buyback: On March 3, 2016, the company announced the suspension of dividends and the commencement of a share buyback program authorized to repurchase up to 10% of its own shares.
• Product Pipeline: Key growth drivers include the FDA clearance of the Troponin I point-of-care test (submitted Dec 2015) and the BNP test (clinical trials ongoing, submission anticipated mid-2016). The company is also developing D-dimer and other emergency medicine assays.
• Capital Allocation: Proceeds from the exchangeable notes are intended for potential acquisitions, general corporate purposes, and continued product development.

• Regulatory Approval: Future growth is heavily dependent on FDA clearance for the Meritas platform (Troponin I and BNP). Delays or denials could materially impact growth.
• Currency Fluctuation: Significant exposure to the Euro, Brazilian Real, and Sterling. A strengthening US Dollar negatively impacts reported revenues and margins.
• Competition: The diagnostics industry is highly competitive with major players (Abbott, Roche, Siemens). Competition may lead to pricing pressure or obsolescence of existing products.
• Supply Chain: Reliance on third-party suppliers for critical components (antibodies, antigens) and third-party manufacturers for certain products creates supply chain risks.
• Healthcare Reform: Changes in Medicare reimbursement rates (e.g., PAMA legislation) and healthcare reform could reduce reimbursement for diagnostic tests.

Important Facts for Investor Verification

• Quality of Earnings: Verify the sustainability of the 2015 net profit increase, which was driven by a $13.0 million non-cash accounting gain on derivative revaluation rather than core operating performance.
• Currency Impact: Assess the sensitivity of future revenues to US Dollar strength, as foreign currency translation significantly reduced 2015 reported revenue.
• Debt Structure: Review the terms of the $115 million exchangeable senior notes (4% coupon, maturity 2045, convertible to ADSs) and the associated dilution risk if converted.
• Dividend Policy: Note the recent suspension of the dividend policy in favor of a share buyback program, signaling a shift in capital return strategy.
• R&D Capitalization: Monitor the capitalization of R&D costs ($19.7 million in 2015) and the associated risk of future impairment if key product launches (Troponin I, BNP) are delayed or fail to gain market acceptance.